NeuroDex research library

Parkinson’s disease and Lewy body dementia: blood biomarker library

Alpha-synuclein is the defining pathology of Parkinson’s disease, Lewy body dementia and multiple system atrophy. Seed amplification assays confirm it in CSF; measuring it in blood, at every visit, is what trials still need. These articles cover diagnosis, enrollment, stratification and target engagement.

Start here

Blood biomarkers for trials

Misdiagnosed at Enrollment: Parkinson’s Look-Alikes in Early-Stage TrialsEarly Parkinson’s trials enroll on a clinical diagnosis that is often wrong. How blood biomarkers, including neuron-derived EV α-synuclein, improve…Parkinson’s Starts a Decade Before Diagnosis. Can Blood Find It?An alpha-synuclein blood test can detect Parkinson’s pathology years before diagnosis. What the data show in prodromal cohorts, and where CSF still…Beyond Alpha-Synuclein: Measuring Neuronal Function to Stratify Parkinson’s PatientsAlpha-synuclein biomarkers show who has Parkinson’s, not why. How neuron-derived EVs measure neuronal function to stratify patients by disease…How to Select Blood Biomarkers for a Parkinson’s TrialBlood biomarkers selection for a Parkinson’s trial depends on the decision the marker must support.Lewy Body Dementia: Building a Blood Biomarker Strategy Without Serial CSFClinical criteria miss 40% of LBD cases and co-pathology is the rule. How to build a blood biomarker panel for Lewy body dementia trials without…Alpha-Synuclein Works. It’s Not Trial-Ready Yet.Plasma alpha-synuclein assays are nearing CSF-level accuracy, but raw plasma still falls short of a trial endpoint. Here is the gap and how to close…Alpha-Synuclein Target Engagement: What CSF and Imaging Can’t Show YouCSF and Imaging Miss Alpha-Synuclein Target Engagement. CSF and DAT imaging diagnose Parkinson’s disease but miss real-time target engagement.Alpha-Synuclein Seed Amplification Assays: The Game-Changer for Early PD Detection and Clinical Trial StratificationDiscover how Alpha-Synuclein Seed Amplification Assays aid in early Parkinson’s disease detection and understanding alpha-synuclein’s role.

NeuroDex research

Clinical trial landscape